Stock events for Tenaya Therapeutics, Inc. (TNYA)
Tenaya Therapeutics' stock has experienced volatility over the past six months. A research collaboration with Alnylam Pharmaceuticals led to a stock price increase. The company participated in the Leerink Partners Global Healthcare Conference 2026 and announced its 2026 Strategic Priorities and Anticipated Milestones. Interim data from the TN-401 trial was shared. A public offering raised $60 million but resulted in share dilution and a stock price decline. The stock closed below $1.00 per share, raising delisting concerns. The FDA granted clearance for a heart failure treatment trial. The company reported GAAP EPS of -$0.69, beating estimates. The stock has a 52-week range between $0.36 and $2.35, with a 90-day share price return decline of 57.39% and a 1-year total shareholder return decline of 44.07%.
Demand Seasonality affecting Tenaya Therapeutics, Inc.’s stock price
Traditional demand seasonality does not directly apply to Tenaya Therapeutics, as it is focused on research and development rather than commercial sales. The demand for its work is driven by the continuous and unmet medical need for treatments for various heart diseases.
Overview of Tenaya Therapeutics, Inc.’s business
Tenaya Therapeutics is a clinical-stage biotechnology company focused on developing curative therapies for heart disease, operating within the Healthcare sector and Biotechnology industry. The company addresses genetic drivers of heart disease through gene therapy, cellular regeneration, and precision medicine. Key product candidates include TN-201 for hypertrophic cardiomyopathy (Phase 2), TN-401 for arrhythmogenic right ventricular cardiomyopathy (Phase 1/1b/2), and TN-301 for heart failure with preserved ejection fraction (Phase 1). Additionally, they are developing gene therapy for dilated cardiomyopathy and a reprogramming program for heart failure post-myocardial infarction.
TNYA’s Geographic footprint
Tenaya Therapeutics is headquartered in South San Francisco, California, and primarily conducts its operations and development activities within the United States.
TNYA Corporate Image Assessment
Tenaya Therapeutics' brand reputation is mixed, reflecting the risks and rewards of a clinical-stage biotechnology company. The research collaboration with Alnylam Pharmaceuticals was seen positively. The company is recognized for its cardiac gene platform and multiple product candidates. Challenges include stock price volatility, a decline in share price, cash burn concerns, and delisting concerns. Analyst ratings are generally positive, with a consensus of "Moderate Buy," though one analyst has issued a "Sell" rating.
Ownership
Tenaya Therapeutics has a diverse ownership structure including institutional investors, insider ownership, and retail investors. Institutional investors hold a significant portion of the stock. Major institutional owners include Column Group LLC, Vanguard Group Inc, Empery Asset Management, LP, Millennium Management Llc, Citadel Advisors Llc, Anson Funds Management LP, Alyeska Investment Group, L.P., BlackRock, Inc., Burkehill Global Management, LP, Kalehua Capital Management LLC, RA Capital Management, L.P., Casdin Partners Master Fund, L.P., and T. ROWE PRICE ASSOCIATES, INC. Insider ownership is also substantial, with Column Group III GP LP being the largest individual shareholder. Retail investors hold a portion of the stock.
